The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4+T cell-priming capacity of dendritic cells
Rheumatology (Oxford). 2015;54(1):169–177
SYK is a core signalling protein that drives inflammatory responses and is fundamental to the propagation of signals via numerous immune receptors. While the clinical development of the first SYK inhibitor, fostamatinib, was stopped due to poor results in the phase 3 RA programme, there remain important questions of mechanism which may aid future developments of this target.
In these murine studies, investigators sought to gain an understanding of how the active metabolite of fostamatini...
In these murine studies, investigators sought to gain an understanding of how the active metabolite of fostamatini...